Statins to improve outcomes in esophageal cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a cholesterol-lowering statin drug (simvastatin or atorvastatin) to standard chemotherapy before surgery can improve survival in patients with advanced esophageal or gastric-junction cancer. Statins may help by reducing inflammation and improving how the body responds to cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with adenocarcinoma (a type of cancer) of the esophagus or where it meets the stomach
- Cancer is locally advanced (stage IIA, IIB, III, or IVA) and can potentially be removed by surgery
- Eligible and willing to receive standard chemotherapy (FLOT regimen) before surgery
- Age 18 or older with good enough overall health to handle chemotherapy and surgery
- No prior cancer of the esophagus or stomach
- Normal or near-normal liver and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations given before and after surgery for people with stomach or gastroesophageal cancer that can be removed but is locally advanced (has grown into nearby tissue). The goal is to see if these combinations can shrink the tumor and improve outcomes.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests if using specific biomarkers (like HER2 and PD-L1) can help choose the best treatment to potentially avoid surgery. It aims to preserve the stomach or esophagus while effectively treating the cancer.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This trial tests combining chemotherapy (FOLFOX) with an immunotherapy drug (Toripalimab) before and after surgery for a type of stomach cancer called HER2-negative adenocarcinoma of the esophagogastric junction. It may help shrink the tumor and improve outcomes.
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.